Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants

Riley Bove,Kerstin Hellwig,Noemi Pasquarelli,Francesco Borriello,Ruth Dobson,Celia Oreja-Guevara,Chien-Ju Lin,Dusanka Zecevic,Licinio Craveiro,Thomas McElrath,Sandra Vukusic

Multiple Sclerosis and Related Disorders（2022）

引用 5|浏览7

暂无评分

摘要

•Limited data are available on the safety of MS therapy during pregnancy and lactation.•Withholding therapy for pregnancy/lactation can lead to MS relapses.•We present 2 studies exploring ocrelizumab in pregnant/lactating women with MS.•The studies will measure B cells and immune responses in infants, alongside comprehensive clinical and biomarker assessments in their mothers.

查看译文

关键词

Multiple sclerosis,Pregnancy,Breastfeeding,Lactation,Ocrelizumab,Disease-modifying therapy,Infant outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要